Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer
- PMID: 36129611
- DOI: 10.1007/s13402-022-00699-0
Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer
Abstract
Purpose: The epidermal growth factor receptor (EGFR) represents a top therapeutic target in the treatment of non-small cell lung cancer. EGFR expression is intricately modulated by receptor endocytosis, during which EGFR ubiquitylation and deubiquitylation play fundamental roles to govern receptor fate. This study aims to uncover novel aspects of the endocytic regulation of EGFR trafficking by deubiquitylases.
Methods: The expression and ubiquitylation of EGFR in non-small cell lung cancer cells treated with deubiquitylase inhibitors were assessed by immunoblotting, immunoprecipitation and mass spectrometry analyses. The intracellular EGFR distribution was investigated using immunofluorescence and confocal microscopy assays, and colocalizations with endocytic compartments were examined using GFP-tagged Rab proteins as markers. The influence of the proteasomal deubiquitylase inhibitor b-AP15 on EGF- and HSP90 inhibitor-induced EGFR downregulation was evaluated by immunoblotting. The anticancer effects of b-AP15 were assessed by cell proliferation, colony formation and flow cytometry assays, as well as xenograft animal models.
Results: We found that b-AP15 caused a dramatically enhanced ubiquitylation of EGFR in lung cancer cells. Treatment with b-AP15 decreased cell surface EGFR levels and accumulated EGFR on recycling endosomes marked with Rab4A and Rab11A. b-AP15 effectively repressed EGF- and HSP90 inhibitor-induced EGFR degradation. Lung cancer cells exposed to b-AP15 showed markedly reduced cell propagation and significantly increased cell apoptosis. Furthermore, b-AP15 effectively inhibited tumor xenograft growth in nude mice.
Conclusion: Proteasomal USP14 and UCHL5 act collectively to promote cell surface recovery of EGFR. Inhibition of proteasomal deubiquitylase activity induces increased EGFR ubiquitylation and retention on recycling endosomes. The USP14 and UCHL5 dual inhibitor b-AP15 elicits potent tumor-suppressive effects to deter cell proliferation and induce apoptotic cell death in lung cancer.
Keywords: EGFR; Endocytic recycling; Non-small cell lung cancer; Proteasomal deubiquitylase; UCHL5; USP14; b-AP15.
© 2022. Springer Nature Switzerland AG.
Similar articles
-
Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells.Acta Pharmacol Sin. 2023 Dec;44(12):2537-2548. doi: 10.1038/s41401-023-01136-0. Epub 2023 Aug 1. Acta Pharmacol Sin. 2023. PMID: 37528233 Free PMC article.
-
Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.Cell Biol Toxicol. 2023 Oct;39(5):2381-2399. doi: 10.1007/s10565-022-09729-x. Epub 2022 Jun 1. Cell Biol Toxicol. 2023. PMID: 35648318
-
Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.J Exp Clin Cancer Res. 2019 Nov 6;38(1):453. doi: 10.1186/s13046-019-1446-y. J Exp Clin Cancer Res. 2019. PMID: 31694672 Free PMC article.
-
Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia.Clin Transl Med. 2022 Sep;12(9):e1038. doi: 10.1002/ctm2.1038. Clin Transl Med. 2022. PMID: 36082692 Free PMC article.
-
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.Blood. 2014 Jan 30;123(5):706-16. doi: 10.1182/blood-2013-05-500033. Epub 2013 Dec 6. Blood. 2014. PMID: 24319254 Free PMC article.
Cited by
-
Clinically relevant stratification of lung squamous carcinoma patients based on ubiquitinated proteasome genes for 3P medical approach.EPMA J. 2024 Mar 4;15(1):67-97. doi: 10.1007/s13167-024-00352-w. eCollection 2024 Mar. EPMA J. 2024. PMID: 38463626 Free PMC article.
-
The effect of ubiquitination and deubiquitination to imatinib resistance in gastrointestinal stromal tumors.Front Oncol. 2025 Jul 25;15:1581920. doi: 10.3389/fonc.2025.1581920. eCollection 2025. Front Oncol. 2025. PMID: 40786504 Free PMC article. Review.
-
The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling.J Exp Clin Cancer Res. 2024 Aug 20;43(1):235. doi: 10.1186/s13046-024-03152-2. J Exp Clin Cancer Res. 2024. PMID: 39164728 Free PMC article.
-
Ceramide Synthase 1 Inhibits Brain Metastasis of Non-Small Cell Lung Cancer by Interacting with USP14 and Downregulating the PI3K/AKT/mTOR Signaling Pathway.Cancers (Basel). 2023 Mar 27;15(7):1994. doi: 10.3390/cancers15071994. Cancers (Basel). 2023. PMID: 37046655 Free PMC article.
-
The Ubiquitin-Proteasome System in Tumor Metabolism.Cancers (Basel). 2023 Apr 20;15(8):2385. doi: 10.3390/cancers15082385. Cancers (Basel). 2023. PMID: 37190313 Free PMC article. Review.
References
-
- S. Ghosh, I. Marrocco, Y. Yarden, Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Adv. Cancer Res. 147, 1–57 (2020) - PubMed
-
- C. Kandoth, M.D. McLellan, F. Vandin, K. Ye, B. Niu, C. Lu, M. Xie, Q. Zhang, J.F. McMichael, M.A. Wyczalkowski, M.D. Leiserson, C.A. Miller, J.S. Welch, M.J. Walter, M.C. Wendl, T.J. Ley, R.K. Wilson, B.J. Raphael, L. Ding, Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013) - PubMed - PMC
-
- N. Cancer Genome Atlas Research, Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014)
-
- S.V. Sharma, D.W. Bell, J. Settleman, D.A. Haber, Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169–181 (2007) - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous